Gene Therapy is fastest growing segment fueling the growth of Transthyretin Amyloid Cardiomyopathy Treatment Market

The global Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1,687.23 Mn in 2023 and is expected to exhibit a CAGR of 31.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Symptoms include heart failure and abnormalities in heart rhythms. The treatment market comprises gene therapies, small molecule drugs and RNA interference therapies aiming to halt production of the misfolded protein or remove the amyloid deposits.

Market key trends:

Gene therapy is gaining traction in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Some of the novel gene therapies in development aim to inhibit production of mutant transthyretin (TTR) protein using RNA interference (RNAi) or antisense oligonucleotides (ASO). For example, Ionis Pharmaceuticals' experimental drug IONIS-TTRRx is currently in phase 3 trials. It uses ASO technology to eliminate production of both mutant and wild-type TTR protein. Positive data could support its approval as the first disease-modifying therapy for ATTR-CM.

Segment Analysis

The Global Transthyretin Amyloid Cardiomyopathy Treatment Market Size is segmented based on drug type, route of administration and distribution channel. Based on drug type, the market is segmented into tafamidis, patisiran and others. Tafamidis segment dominated the market in 2023 due to its higher efficacy and approval for treatment of ATTR-CM.

Key Takeaways

The global transthyretin amyloid cardiomyopathy treatment market is expected to witness high growth, exhibiting CAGR of 31. % over the forecast period, due to increasing prevalence of ATTR-CM and limited treatment options.

North America dominated the global market in 2023 and is expected to maintain its dominance during the forecast period. This is attributed to growing awareness regarding ATTR-CM diagnosis and approvals of novel ATTR-CM therapies in the region.

Key players operating in the transthyretin amyloid cardiomyopathy treatment market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.

Read Our More Blogs : https://www.rapidwebwire.com/transthyretin-amyloid-cardiomyopathy-treatment-market-size-share-analysis-2023-2030/